基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02616 基石药业-B

未开盘 12-20 16:08:10

2.300

-0.040

-1.71%

最高2.430	最低2.280	成交量243.25万
今开2.340	昨收2.340	日振幅6.41%
总市值29.54亿	流通市值29.54亿	总股本12.84亿
成交额571.76万	换手率0.19%	流通股本12.84亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":2.3,"timestamp":1734682090015,"preClose":2.34,"halted":0,"volume":2432500,"delay":0,"floatShares":1284207212,"shares":1284207212,"eps":-0.30997944,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.04,"latestTime":"12-20 16:08:10","open":2.34,"high":2.43,"low":2.28,"amount":5717590,"amplitude":0.064103,"askPrice":2.31,"askSize":4500,"bidPrice":2.3,"bidSize":15000,"shortable":0,"etf":0,"ttmEps":-0.11900389341044594,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"listingDate":1551110400000,"adjPreClose":2.34,"openAndCloseTimeList":[[1734658200000,1734667200000],[1734670800000,1734681600000]],"volumeRatio":0.4676430065681562,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616/wiki","defaultTab":"wiki","newsList":[{"id":"2492142862","title":"基石药业-B12月19日主力资金流出181万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2492142862","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492142862?lang=zh_cn&edition=full","pubTime":"2024-12-19 16:16","pubTimestamp":1734596174,"startTime":"0","endTime":"0","summary":"12月19日, 基石药业-B股价跌8.59%，报收2.34元，成交金额805万元，换手率0.26%，振幅8.59%，量比0.57。基石药业-B今日主力资金净流出181万元，连续5日净流出，上一交易日主力净流出200万元，今日环比减少9.50%。近一年数据显示，该股主力连续5日净流出后，次日下跌概率为66.67%，平均跌幅为2.34%。该股近5个交易日下跌11.07%，主力资金累计净流出654万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入564万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219162730ab83f031&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219162730ab83f031&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2492194102","title":"基石药业-B(02616)下跌5.08%，报2.43元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492194102","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492194102?lang=zh_cn&edition=full","pubTime":"2024-12-19 11:12","pubTimestamp":1734577927,"startTime":"0","endTime":"0","summary":"12月19日，基石药业-B(02616)盘中下跌5.08%，截至11:12，报2.43元/股，成交173.45万元。基石药业主要专注于抗肿瘤药物的研发，以满足中国和全球癌症患者的医疗需求，目前已经成功上市4款创新药，获批14项新药上市申请以及9项适应症，并且在研发管线中包括12款候选药物。公司具有一支全面覆盖药物发现、研发、生产和商业运营等关键环节的专业团队。截至2024年中报，基石药业-B营业总收入2.54亿元、净利润1569.9万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/19111246573937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"2492194907","title":"基石药业-B盘中异动 股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492194907","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492194907?lang=zh_cn&edition=full","pubTime":"2024-12-19 11:12","pubTimestamp":1734577920,"startTime":"0","endTime":"0","summary":"2024年12月19日早盘11时12分，基石药业-B股票出现异动，股价大幅下跌5.08%。截至发稿，该股报2.430港元/股，成交量69.8万股，换手率0.05%，振幅4.69%。基石药业-B股票所在的生物技术行业中，整体跌幅为0.96%。其相关个股中，来凯医药-B、永泰生物-B、思路迪医药股份涨幅较大，振幅较大的相关个股有来凯医药-B、晶泰控股-P、永泰生物-B，振幅分别为18.50%、13.59%、12.28%。基石药业-B公司简介：基石药业是一家中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219111203ab8361d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219111203ab8361d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"2492164383","title":"基石药业(02616.HK)治疗淋巴瘤药物临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2492164383","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492164383?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:14","pubTimestamp":1734567240,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK) 公布，旗下管线2.0重磅产品“CS5001(ROR1ADC)”全球多中心Ib期临床试验完成首例患者入组。据介绍，CS5001是目前已知首个在实体瘤和淋巴瘤中，均观察到临床抗肿瘤疗效的ROR1 ADC，其临床开发进展位于全球前二。临床数据显示，CS5001作为单药治疗侵袭性和惰性晚期淋巴瘤的客观缓解率高于同类竞品，具有快速注册上市及冲击一线联合治疗格局的潜力。另外，CS5001全球多中心试验在美国、澳洲及中国同步进行，目前已推进至Ib期进行剂量优化，后续潜在扩展为II期单臂注册研究。(js/w)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230626115201047_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230626115201047_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405109/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1576","BK1161","BK1141","BK1574","02616","BK1583","03347"],"gpt_icon":0},{"id":"2492613731","title":"基石药业-B(02616)：CS5001(ROR1 ADC)全球多中心Ib期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2492613731","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492613731?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:08","pubTimestamp":1734566916,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司管线2.0重磅产品CS5001全球多中心Ib期临床试验顺利完成首例患者入组。截至目前，CS5001在Ia期10个剂量组的剂量递增试验评估中，已展现出良好的安全性及明显的抗肿瘤活性。此外，在晚期实体瘤中，例如非小细胞肺癌、胰腺癌等，也观察到CS5001明显的疗效信号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","ADC","BK1583","02616","BK4231","BK1141","BK1576","BK4080","BK1161","BK1574"],"gpt_icon":0},{"id":"2492094132","title":"基石药业-B(02616)下跌5.24%，报2.53元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492094132","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492094132?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:40","pubTimestamp":1734486059,"startTime":"0","endTime":"0","summary":"12月18日，基石药业-B(02616)盘中下跌5.24%，截至09:40，报2.53元/股，成交139.79万元。基石药业主要专注于抗肿瘤药物的研发，以满足中国和全球癌症患者的医疗需求，目前已经成功上市4款创新药，获批14项新药上市申请以及9项适应症，并且在研发管线中包括12款候选药物。公司具有一支全面覆盖药物发现、研发、生产和商业运营等关键环节的专业团队。截至2024年中报，基石药业-B营业总收入2.54亿元、净利润1569.9万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/18094046520826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2492949959","title":"基石药业-B盘中异动 早盘急速下跌5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492949959","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492949959?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:40","pubTimestamp":1734486055,"startTime":"0","endTime":"0","summary":"2024年12月18日早盘09时40分，基石药业-B股票出现波动，股价快速下跌5.24%。截至发稿，该股报2.530港元/股，成交量54.2万股，换手率0.04%，振幅5.24%。资金方面，该股资金流入5.1145万港元，流出129.547万港元。基石药业-B股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，百奥赛图-B、帝王国际投资、绿竹生物-B涨幅较大，振幅较大的相关个股有永泰生物-B、帝王国际投资、晶泰控股-P，振幅分别为14.23%、5.88%、5.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218094055984c9ae3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218094055984c9ae3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2492862941","title":"基石药业－Ｂ(02616)股价下跌5.243%，现价港币$2.53","url":"https://stock-news.laohu8.com/highlight/detail?id=2492862941","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492862941?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:40","pubTimestamp":1734486000,"startTime":"0","endTime":"0","summary":"[下跌股]基石药业－Ｂ(02616) 股价在上午09:40比前收市价下跌5.243%，现股价为港币$2.53。至目前为止，今日最高价为$2.67，而最低价为$2.53。总成交量为43.6万股，总成交金额为港币$112.74万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD241218163/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2492987082","title":"基石药业-B12月17日遭主力抛售187万元 环比增加136.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492987082","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492987082?lang=zh_cn&edition=full","pubTime":"2024-12-17 16:16","pubTimestamp":1734423416,"startTime":"0","endTime":"0","summary":"12月17日, 基石药业-B股价跌1.48%，报收2.67元，成交金额1601万元，换手率0.46%，振幅6.64%，量比0.96。基石药业-B今日主力资金净流出187万元，连续3日净流出，上一交易日主力净流出79万元，今日环比增加136.71%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为50.00%，平均跌幅为2.70%。该股近5个交易日上涨16.74%，主力资金累计净流入100万元；近20日主力资金累计净流入832万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217161754a1f543ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217161754a1f543ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2491913659","title":"基石药业-B12月16日遭主力抛售79万元 环比增加777.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491913659","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491913659?lang=zh_cn&edition=full","pubTime":"2024-12-16 16:16","pubTimestamp":1734336978,"startTime":"0","endTime":"0","summary":"12月16日, 基石药业-B股价涨3.04%，报收2.71元，成交金额2338万元，换手率0.67%，振幅6.08%，量比1.70。基石药业-B今日主力资金净流出79万元，上一交易日主力净流出9万元，今日环比增加777.78%。该股近5个交易日上涨18.26%，主力资金累计净流入351万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入994万元，其中净流入天数为9日。该股主力净额占比0.02%，港股市场排名2483/2651。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161657ab7bc976&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161657ab7bc976&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2491638444","title":"基石药业-B(02616)上涨5.32%，报2.77元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491638444","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491638444?lang=zh_cn&edition=full","pubTime":"2024-12-16 11:37","pubTimestamp":1734320225,"startTime":"0","endTime":"0","summary":"12月16日，基石药业-B(02616)盘中上涨5.32%，截至11:37，报2.77元/股，成交1513.2万元。基石药业主要专注于抗肿瘤药物的研发，以满足中国和全球癌症患者的医疗需求，目前已经成功上市4款创新药，获批14项新药上市申请以及9项适应症，并且在研发管线中包括12款候选药物。公司具有一支全面覆盖药物发现、研发、生产和商业运营等关键环节的专业团队。截至2024年中报，基石药业-B营业总收入2.54亿元、净利润1569.9万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/16113746410272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2491063883","title":"基石药业-B盘中异动 临近午盘快速上涨5.32%报2.770港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491063883","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491063883?lang=zh_cn&edition=full","pubTime":"2024-12-16 11:36","pubTimestamp":1734320217,"startTime":"0","endTime":"0","summary":"2024年12月16日临近午盘11时36分，基石药业-B股票出现波动，股价急速拉升5.32%。截至发稿，该股报2.770港元/股，成交量562.179万股，换手率0.44%，振幅6.08%。资金方面，该股资金流入678.266万港元，流出746.436万港元。基石药业-B股票所在的生物技术行业中，整体跌幅为1.07%。其相关个股中，华康生物医学、晶泰控股-P、基石药业-B涨幅较大，振幅较大的相关个股有创胜集团-B、思路迪医药股份、华康生物医学，振幅分别为18.03%、15.11%、13.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216113657ab7b413e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216113657ab7b413e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2491680204","title":"基石药业-B现涨逾4% 将于ASH年会公布CS5001针对晚期淋巴瘤最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2491680204","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491680204?lang=zh_cn&edition=full","pubTime":"2024-12-16 11:29","pubTimestamp":1734319740,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　基石药业-B（02616）早盘上涨3.80%，现报2.73港元，成交额1450.93万港元。\n　　近日，基石药业-B公布，将在第66届美国血液学会（ASH）年会上，公布管线2.0重磅产品CS5001（ROR1 ADC）针对淋巴瘤的最新临床数据。公告指出，CS5001是目前已知首个在实体瘤和淋巴瘤中均观察到临床疗效的ROR1 ADC。本次ASH年会的公布突出CS5001作为单药治疗晚期淋巴瘤的最新安全性和疗效数据。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-16/doc-inczrkux2813318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02616","BK1161","LU2463526074.USD","ASH","BK1574","BK4109"],"gpt_icon":0},{"id":"2491680666","title":"港股异动 | 基石药业-B(02616)涨超3% 将于ASH年会公布CS5001针对晚期淋巴瘤最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2491680666","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491680666?lang=zh_cn&edition=full","pubTime":"2024-12-16 11:23","pubTimestamp":1734319420,"startTime":"0","endTime":"0","summary":"消息面上，近日，基石药业-B公布，将在第66届美国血液学会年会上，公布管线2.0重磅产品CS5001针对淋巴瘤的最新临床数据。公告指出，CS5001是目前已知首个在实体瘤和淋巴瘤中均观察到临床疗效的ROR1 ADC。本次ASH年会的公布突出CS5001作为单药治疗晚期淋巴瘤的最新安全性和疗效数据。另外，CS5001全球多中心临床试验目前仍在美国、澳洲和中国同步进行，目前剂量递增已完成，近期公司将启动涵盖多瘤种、具有注册潜力的Ib期剂量扩展研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ASH","BK1161","BK4109","BK1574","LU2463526074.USD","02616"],"gpt_icon":0},{"id":"2491685330","title":"广州生物岛告欠租900万明星企业，催租“紧箍咒”备受质疑","url":"https://stock-news.laohu8.com/highlight/detail?id=2491685330","media":"南方都市报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491685330?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:09","pubTimestamp":1734311345,"startTime":"0","endTime":"0","summary":"前言：有消息传出，今年以来，广州生物岛已起诉一批欠租企业。南都记者登录广州海珠区法院检索开庭公告后发现，至少有七家企业涉及租赁合同纠纷，被广州国际生物岛集团有限公司（下简称“生物岛集团”）起诉。而中国裁判文书网上的信息显示，此前因欠租而被生物岛集团起诉的企业不过是两三家而已。在这批因欠租而被起诉的企...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/O-yX9WIzQsR8OGIoXyvw79W6ki0ky3Ieb37CFMuceS3NQAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/O-yX9WIzQsR8OGIoXyvw79W6ki0ky3Ieb37CFMuceS3NQAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241216A023LU00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241216A023LU00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK1229","BK4122","BK4585","02616","06958","BK4524","09983","01971","BK4588","BK1583","W","09966","BK1542","BK4548","BK4178","BK4561","BK1574","BK1258","BK1161"],"gpt_icon":0},{"id":"2490514879","title":"基石药业-B12月12日主力资金流入217万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2490514879","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490514879?lang=zh_cn&edition=full","pubTime":"2024-12-12 16:17","pubTimestamp":1733991429,"startTime":"0","endTime":"0","summary":"12月12日, 基石药业-B股价涨8.26%，报收2.62元，成交金额1632万元，换手率0.50%，振幅11.16%，量比1.76。基石药业-B今日主力资金净流入217万元，连续5日净流入，上一交易日主力净流入156万元，今日环比增加39.10%。该股近5个交易日上涨21.30%，主力资金累计净流入628万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1072万元，其中净流入天数为10日。该股主力净额占比0.06%，港股市场排名108/2652。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212161825ab71dfae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212161825ab71dfae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2490827940","title":"基石药业-B(02616)上涨5.37%，报2.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490827940","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490827940?lang=zh_cn&edition=full","pubTime":"2024-12-12 14:26","pubTimestamp":1733984802,"startTime":"0","endTime":"0","summary":"12月12日，基石药业-B(02616)盘中上涨5.37%，截至14:26，报2.55元/股，成交842.96万元。基石药业主要专注于抗肿瘤药物的研发，以满足中国和全球癌症患者的医疗需求，目前已经成功上市4款创新药，获批14项新药上市申请以及9项适应症，并且在研发管线中包括12款候选药物。公司具有一支全面覆盖药物发现、研发、生产和商业运营等关键环节的专业团队。截至2024年中报，基石药业-B营业总收入2.54亿元、净利润1569.9万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/12142646306396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2490882075","title":"基石药业-B盘中异动 下午盘急速拉升5.37%报2.550港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490882075","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490882075?lang=zh_cn&edition=full","pubTime":"2024-12-12 14:26","pubTimestamp":1733984801,"startTime":"0","endTime":"0","summary":"2024年12月12日下午盘14时26分，基石药业-B股票出现波动，股价急速拉升5.37%。截至发稿，该股报2.550港元/股，成交量342.45万股，换手率0.27%，振幅7.44%。资金方面，该股资金流入456.183万港元，流出277.815万港元。基石药业-B股票所在的生物技术行业中，整体涨幅为0.01%。其相关个股中，思路迪医药股份、晶泰控股-P、帝王国际投资涨幅较大，振幅较大的相关个股有思路迪医药股份、晶泰控股-P、帝王国际投资，振幅分别为38.70%、19.44%、18.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212142641984b8165&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212142641984b8165&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2490545000","title":"基石药业-B(02616)上涨5.29%，报2.39元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490545000","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490545000?lang=zh_cn&edition=full","pubTime":"2024-12-11 13:23","pubTimestamp":1733894605,"startTime":"0","endTime":"0","summary":"12月11日，基石药业-B(02616)盘中上涨5.29%，截至13:23，报2.39元/股，成交629.18万元。基石药业主要专注于抗肿瘤药物的研发，以满足中国和全球癌症患者的医疗需求，目前已经成功上市4款创新药，获批14项新药上市申请以及9项适应症，并且在研发管线中包括12款候选药物。公司具有一支全面覆盖药物发现、研发、生产和商业运营等关键环节的专业团队。截至2024年中报，基石药业-B营业总收入2.54亿元、净利润1569.9万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/11132346248165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2490000171","title":"基石药业-B盘中异动 股价大涨5.29%报2.390港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490000171","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490000171?lang=zh_cn&edition=full","pubTime":"2024-12-11 13:23","pubTimestamp":1733894602,"startTime":"0","endTime":"0","summary":"2024年12月11日下午盘13时23分，基石药业-B股票出现异动，股价大幅上涨5.29%。截至发稿，该股报2.390港元/股，成交量275.697万股，换手率0.21%，振幅7.49%。资金方面，该股资金流入400.533万港元，流出85.9725万港元。基石药业-B股票所在的生物技术行业中，整体跌幅为0.46%。其相关个股中，科济药业-B、北海康成-B、百奥赛图-B涨幅较大，振幅较大的相关个股有北海康成-B、科济药业-B、创胜集团-B，振幅分别为45.77%、25.62%、14.29%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211132322ab6e9bb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211132322ab6e9bb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":-0.1255},{"period":"1month","weight":0.1558},{"period":"3month","weight":0.5646},{"period":"6month","weight":1.1101},{"period":"1year","weight":0.055},{"period":"ytd","weight":0.0132}],"compareEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0801},{"period":"6month","weight":0.0939},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1568}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家中国投资控股公司。该公司通过子公司主要从事生物制药产品的研发、生产和销售业务。该公司主要产品是肿瘤免疫治疗疗法和分子靶向药物。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.078236},{"month":2,"riseRate":0.2,"avgChangeRate":-0.045216},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.116412},{"month":4,"riseRate":0.2,"avgChangeRate":-0.028106},{"month":5,"riseRate":0.4,"avgChangeRate":0.039766},{"month":6,"riseRate":0.666667,"avgChangeRate":0.097121},{"month":7,"riseRate":0.5,"avgChangeRate":-0.049356},{"month":8,"riseRate":0.333333,"avgChangeRate":0.010588},{"month":9,"riseRate":0.5,"avgChangeRate":-0.033892},{"month":10,"riseRate":0.5,"avgChangeRate":0.015157},{"month":11,"riseRate":0.666667,"avgChangeRate":0.016123},{"month":12,"riseRate":0.5,"avgChangeRate":0.028191}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}